Log In
Print this Print this

Ixinity, trenonacog alfa (IB1001)

  Manage Alerts
Collapse Summary General Information
Company Aptevo Therapeutics Inc.
DescriptionRecombinant coagulation Factor IX (rFIX)
Molecular Target Factor IX
Mechanism of ActionFactor IX replacement
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients with hemophilia B; Treat bleeding associated with hemophilia B
Regulatory Designation U.S. - Undisclosed Review (Treat and prevent bleeding in patients with hemophilia B)
PartnerIpsen Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today